Novel immunotherapy strategies for multiple myeloma and other haematological malignancies

Ned Tijdschr Klin Chem Labgeneesk 2012, vol. 37, no. 1 22. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. Eerst prikken, dan slikken. Pharmaceutisch Weekblad. 2001; 136: 565-569. 23. www.cypalleles.ki.se. 24. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J. 2010.xxxxxc 25. Hinrichs JW, Loovers HM, Scholten B, van der WJ. Semiquantitative CYP2D6 gene doses in relation to meta bolic ratios of psychotropics. Eur J Clin Pharmacol. 2008; 64: 979-986. 26. Weide van der J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit. 2005; 27: 478-483. 27. Schillevoort I, de mmmm BA, van der Weide J, Steijns LS, Roos RA, Jansen PA et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002; 12: 235-240. 28. Swen J J, Huizinga TW, Gelderblom H., de Vries EGE, Assendelft WJJ, Kirchheiner J. et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Medicine. 2007; 4: 1317-1323. 29. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008; 83: 781-787. 30. Loovers HM, van Weelden MJ, van der Weide J. Handleiding voor toepassen van farmacogenetica in de psychiatrie: het ALERT protocol. Ned Tijdschr Klin Chem Labgeneesk. 2011; 36: 145-152. 31. Kootstra-Ros JE, van Weelden MJ, Hinrichs JW, De Smet PA, van der Weide J. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol. 2006; 46: 1320-1327.